• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

30.77 +1.00 (+3.36%)
Delayed Quote Updated: 1:12 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 541,537
Open 29.83
Bid (Size) 30.75 (100)
Ask (Size) 30.81 (100)
Prev. Close 29.77
Today's Range 29.83 - 31.60
52wk Range 21.02 - 43.25
Shares Outstanding 33,816,459
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
October 08, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
October 05, 2026
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options 
From Pharvaris N.V.
Via GlobeNewswire

Performance

52-Week Range 28.9% below 52-week high
30.77
21.0252W Low 43.2552W High
1 Week 1.4% below 1-week high
27.681W Low 31.201W High

Pharvaris N.V. - Ordinary Shares (PHVS) traded between $21.02 and $43.25 over the past 52 weeks and last traded at $30.77, 28.9% below its 52-week high. Over the past week it ranged between $27.68 and $31.20.

Past 12 Months
+2.5%
-14.6%
-8.3%
+6.2%
+16.2%
+30.2%
1W +$0.75
1M -$5.25
3M -$2.78
6M +$1.80
YTD +$4.29
1Y +$7.14

PHVS was +30.2% over the past year, +6.2% over six months, +16.2% year to date, +2.5% in the last week.

12 Months vs Market
PHVS
+30.2%
DIA
+12.1%
SPY
+14.5%
QQQ
+17.4%
IWM
+11.0%

Over the past 12 months PHVS returned +30.2% versus DIA (Dow) +12.1%, SPY (S&P 500) +14.5%, QQQ (Nasdaq 100) +17.4% and IWM (Russell 2000) +11.0%.

Volume & Liquidity 0.72× 3-mo avg
Today 541,537 3-mo avg 752.1K
1W
777.9K
1M
695.1K
3M
752.1K
6M
596.1K
YTD
441.1K
1Y
424.8K

PHVS most recently traded 541,537 shares against a 3-month average daily volume of 752.1K.

More News

Read More
News headline image
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
September 08, 2026
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones ↗
April 02, 2026
Via Chartmill
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
September 06, 2026
Via MarketBeat
Topics Artificial Intelligence Bonds
News headline image
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 03, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
August 06, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? ↗
July 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
July 22, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 06, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
June 15, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Annual General Meeting of Shareholders
June 11, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
May 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
May 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 ↗
May 11, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 11, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
May 08, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next ↗
April 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. ↗
April 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 02, 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026
From Pharvaris N.V.
Via GlobeNewswire

Frequently Asked Questions

Is Pharvaris N.V. - Ordinary Shares publicly traded?
Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.
What exchange does Pharvaris N.V. - Ordinary Shares trade on?
Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?
The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market
What is the current price of Pharvaris N.V. - Ordinary Shares?
The current price of Pharvaris N.V. - Ordinary Shares is 30.77
When was Pharvaris N.V. - Ordinary Shares last traded?
The last trade of Pharvaris N.V. - Ordinary Shares was at 10/20/26 01:12 PM ET
What is the market capitalization of Pharvaris N.V. - Ordinary Shares?
The market capitalization of Pharvaris N.V. - Ordinary Shares is 1.04B
How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?
Pharvaris N.V. - Ordinary Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap